LIVER fibrosis
Overview
Liver fibrosis is a multifactorial disease, and the development of an effective therapy requires not only consideration of the full spectrum of biological disturbances (factors) associated with the condition but also their ranking by significance, with mandatory evaluation of the scientific and experimental evidence supporting each.
Pathogenesis
​
The pathogenesis of liver fibrosis adopted in this project is largely consistent with the accepted scientific framework and includes the following stages:
​​
-
Accumulation of lipids in hepatocytes (steatosis);
-
Oxidative stress and hepatocellular injury;
- Development of inflammation (steatohepatitis, NASH);
-
Formation of hepatic fibrosis;
- Progression to cirrhosis and hepatocellular carcinoma (HCC).
Project Strategy
The project aims to develop a therapeutic product that directly targets the key biological processes underlying liver fibrosis—processes for which no approved drugs currently exist.
The primary therapeutic objectives include:
​
-
Utilization / phagocytosis of fibrotic liver tissue;
-
Regeneration of damaged hepatocytes.
For more information,
see our presentation: download here
Licensing Service:
We offer cost-effective licensing of our proprietary vector technology to external partners. For more information on how to license our vector, please contact us here.
